Biosynthesis of Furocoumarins: Further Studies on Ruta Graveolens

Total Page:16

File Type:pdf, Size:1020Kb

Biosynthesis of Furocoumarins: Further Studies on Ruta Graveolens BIOSYNTHESIS OF FUROCOUMARINS 813 Biosynthesis of Furocoumarins: Further Studies on Ruta graveolens F. DALL'ACQUA, A. CAPOZZI, S. MARCIANI, and G. CAPORALE Institute of Pharmaceutical Chemistry of the University, Centro di Studio per la Chimica del Farmaco e dei Prodotti biologicamente attivi del Consiglio Nazionale delle Ricerche, Padua (Italy) (Z. Naturforsch. 27 b, 813—817 [1972]; received March 20/April 24, 1972) The Authors have studied the biosynthesis of some furocoumarins contained in Ruta graveolens. Labeled 5,7- and 7,8-dihydroxycoumarins have been administered to the herb, however practically no incorporation of radioactivity was observed in the isolated furocoumarins. Moreover, with the aim to study in a more detailed way the role of rutaretin and marmesin, trapping experiments have been performed administering to the herb labeled umbelliferone together with unlabeled rutaretin and marmesin respectively. A very effective incorporation was observed into marmesin, in lesser extent into rutaretin. In trapping experiments carried out using labeled rutaretin together with unlabeled marmesin and "vice versa", the results obtained clearly show that while marmesin was converted into ruta- retin in a very effective way, rutaretin was transformed into marmesin only in a smaller extent. The Authors suggest the biogenetic origin of rutaretin and moreover formulate a new and more detailed aspect of the scheme for the biosynthetic pathway of furocoumarins in Ruta graveolens. The biogenesis of furocoumarins has been studied (III); from this compound other naturally occur- in various plants [Ficus carica 2, Pimpinella ring furocoumarins, for instance bergapten (IV) magna3'4, Ammi majus, Angelica archangelica, and xanthotoxin (V) can derive by means of hy- Heracleum lanatum, Ruta graveolens 5-9, Pastinaca droxylation and O-alkylation reactions. sativa10]. The general scheme of the biosynthetic More recently we have found that not only hy- pathway appears to be well established: it involves droxylation and O-alkylation reactions, but also de- in a first stage the formation of a 7-hydroxycouma- methoxylation reactions can take place in plants: in rin-derivative (the biogenesis of coumarins has fact we have observed that a reciprocal conversion already been largely studied); successively the furan between psoralen and xanthotoxin can occur6; ring is formed on this compound through an iso- moreover, 4',5' - dihydropsoralen, 4',5' - dihydro- prenylation reaction leading to a 4',5'-dihydrofuro- bergapten and 4/,5'-dihydroxanthotoxin proved to coumarin-intermediate; finally this last is trans- be precursors not only of the corresponding furo- formed into furocoumarin-derivative. coumarins (psoralen, bergapten and xanthotoxin, It has been found that 7-hydroxycoumarin (I) respectively) but also of the other two, although (umbelliferone) is the most effective general pre- only to a small extent5. cursor at the first stage. Recently BROWN 7- 8 sug- Concerning Ruta graveolens, some doubt could gested that the only natural intermediate at the stage arise about the preceding biogenetic scheme, be- of 4',5'-dihydrofurocoumarin-derivative is marme- cause marmesin till now has not been found present sin (II), which is then transformed into psoralen in this plant, although feeding experiments have OCH3 / ykAA, IV ovo v CH3 ^ II IH O'^V^O'^'O Fig. 1. General biosynthetic 0CH3 pathway proposed for psoralen V (III), bergapten(IV) and xantho- toxin (V). Requests for reprints should be sent to Dr. F. DALL'ACQUA, Universitä di Padova, Istituto di Chimica Farmaceutica, Via Marzolo 5, 35100 Padova (Italy). 814 F. DALL'ACQUA, A. CAPOZZI, S. MARCIANI, AND G. CAPORALE demonstrated that it may be a valid precursor for experiment was comprehended between the range furocoumarins (psoralen, bergapten and xantho- 10 —12 g. This was placed into 100 ml beakers con- taining a mixture formed by adding to the aqueous toxin) and especially for psoralen. On the other solution of the labeled compound to be administered, hand, another 4 ,5 -dihydrofurocoumarin-derivative an equal volume of an "aqueous nutritious solution" 17. has been isolated from Ruta graveolens, that is ruta- The system was illuminated with 500 W Osram HWL retin (VI), which is an 8-hydroxyderivative of mar- lamps; "metabolism time" lasted 7 days for feeding experiments with umbelliferone and its hydroxy- mesin n. derivatives, while for trapping experiments it lasted 54 hours. During the metabolic period "aqueous nutri- tious solution" was added to maintain constant the level of the liquid layer in the beakers. 3 OH VI Trapping experiments Fig. 2. Molecular structure of rutaretin (VI). Two different types of trapping experiments have been performed A) and B) : Very recently we have found that rutaretin (VI) A) 2.4 mg of tritiated umbelliferone was solubilized is well incorporated specifically into xanthotoxin in 40 ml of distilled water and successively 16 mg of unlabeled rutaretin was also dissolved in the same and also into psoralen and bergapten, even to a solution and this was administered to the herb as indi- 6 lesser extent . It may therefore be the natural cated in the section "feeding procedure". Analogous 4',5'-dihydrofurocoumarin-intermediate, at least for experiment was performed using unlabeled marmesin the biosynthesis of xanthotoxin. (15 mg) together with tritiated umbelliferone (2.6 mg); The studies reported in this paper have been per- B) 3 mg of tritiated rutaretin together with 10 mg of unlabeled marmesin were solubilized in 40 ml of formed to obtain further experimental information distilled water and this solution was then administered on the role of rutaretin, on its biogenetic origin and to Ruta graveolens as reported in the "feeding proce- on the possibility that marmesin also may be a phy- dure". Parallel experiment was carried out using 3 mg siological intermediate, perhaps present only in a of tritiated marmesin and 10 mg of unlabeled rutaretin, operating in the same experimental conditions. very small amount. The results obtained feeding Ruta graveolens with Isolation and purification of furocoumarins and of 5,7-dihydroxycoumarin (VII) and with 7,8-dihy- rutaretin and marmesin droxycoumarin (VIII) (daphnetin), as well as per- Isolation and purification of psoralen (III), bergap- forming some trapping experiments, in which marme- ten (IV) and xanthotoxin (V) were performed fol- lowing a procedure described elsewhere 6. sin and rutaretin were involved, allowed us to for- Rutaretin (VI) and marmesin (II) were isolated mulate a more detailed scheme for the biosynthetic and purified in a way similar to that described for pathway of psoralen and xanthotoxin in Ruta gra- furocoumarins with little change in the procedure for veolens. preparing the "coumarinic extract"1,2'18 as follows: the etheral coumarinic extract was washed three times with an equal volume of saturated sodium bicarbonate Materials and Methods aqueous solution. After this treatment, while marmesin and furocoumarins remained in the etheral solution 7-hydroxycoumarin or umbelliferone (I) 12, 5,7-di- (A), rutaretin passed into the aqueous bicarbonate hydroxycoumarin (VII) 13 and 7,8-dihydroxycoumarin phase; this last phase was acidified with 2n HCl and (VIII) 14 have been prepared in this Institute. then extracted with ether (B). From the two etheral Rutaretin (VI) 11 (extracted from Ruta graveo- 15 extracts (A) and (B) the solvent was distilled and the lens) and marmesin (II) (extracted from Aegle mar- residues were chromatographed as follows: melos, Correa) have kindly been provided by Prof. Dr. a) thin layer silica gel preparative chromatography G. SCHNEIDER and Prof. Dr. A. CHATTERJEE respecti- vely. 3H labeling procedure of all these substances has (Merck cat. 5717) using as solvent of development ethyl acetate : cyclohexane (3 : 1, v/v) ; been carried out according to the WILZBACH method 16. Chemical and radiochemical purification of labeled b) thin layer silica gel analytical chromatography compounds has been performed following a procedure (Merck cat. 5715) : solvent of development ethyl ace- described elsewhere 2. The specific radioactivity of these tate : cyclohexane (2 : 1, v/v) : at this stage chemical compounds is reported in Tables I, II and III. and radiochemical purity of the substances were tested. Spectrophotometrical measurements and radiochemical Feeding procedure determinations Cut ends of Ruta graveolens herb were employed; The different ethanolic solutions containing the generally the dry weight of this material for every various isolated compounds were examined spectro- BIOSYNTHESIS OF FUROCOUMARINS 815 photometrically both recording their u.v. spectra using It is well known that the biogenetic route starting a 124 double beam model Perkin-Elmer instrument and from umbelliferone and leading to furocoumarins successively determining their absorbance at X max involves 4',5'-dihydrointermediates; in the case of by means of a CF 4 Optica single beam spectro- photometer. Radiochemical measurements were per- Ruta graveolens recently it has been shown 6- 8 that, formed by a liquid scintillator spectrophotometer at this stage, marmesin (II) and rutaretin (VI) are model 3375 Packard using a dioxane base scintillator: involved. However while rutaretin is present in a naphthalene g 120, 2,5-diphenyl-oxazole g 4, 2,2'-p- valuable extent in this herb11 marmesin has not phenylen bis (5-phenyl-oxazole) g 0.075 in dioxane been till now identified. up to 1000 ml of solution. The apparatus efficiency in experimental
Recommended publications
  • Phototoxicity of 7-Oxycoumarins with Keratinocytes in Culture T ⁎ Christophe Guillona, , Yi-Hua Janb, Diane E
    Bioorganic Chemistry 89 (2019) 103014 Contents lists available at ScienceDirect Bioorganic Chemistry journal homepage: www.elsevier.com/locate/bioorg Phototoxicity of 7-oxycoumarins with keratinocytes in culture T ⁎ Christophe Guillona, , Yi-Hua Janb, Diane E. Heckc, Thomas M. Marianob, Robert D. Rappa, Michele Jettera, Keith Kardosa, Marilyn Whittemored, Eric Akyeaa, Ivan Jabine, Jeffrey D. Laskinb, Ned D. Heindela a Department of Chemistry, Lehigh University, Bethlehem, PA 18015, USA b Department of Environmental and Occupational Health, Rutgers University School of Public Health, Piscataway, NJ 08854, USA c Department of Environmental Science, New York Medical College, Valhalla, NY 10595, USA d Buckman Laboratories, 1256 N. McLean Blvd, Memphis, TN 38108, USA e Laboratoire de Chimie Organique, Université Libre de Bruxelles, B-1050 Brussels, Belgium ARTICLE INFO ABSTRACT Keywords: Seventy-one 7-oxycoumarins, 66 synthesized and 5 commercially sourced, were tested for their ability to inhibit 7-hydroxycoumarins growth in murine PAM212 keratinocytes. Forty-nine compounds from the library demonstrated light-induced 7-oxycoumarins lethality. None was toxic in the absence of UVA light. Structure-activity correlations indicate that the ability of Furocoumarins the compounds to inhibit cell growth was dependent not only on their physiochemical characteristics, but also Psoralens on their ability to absorb UVA light. Relative lipophilicity was an important factor as was electron density in the Methoxsalen pyrone ring. Coumarins with electron withdrawing moieties – cyano and fluoro at C – were considerably less 8-MOP 3 Phototoxicity active while those with bromines or iodine at that location displayed enhanced activity. Coumarins that were PAM212 keratinocytes found to inhibit keratinocyte growth were also tested for photo-induced DNA plasmid nicking.
    [Show full text]
  • Phototoxicity of 7-Oxycoumarins with Keratinocytes in Culture T ⁎ Christophe Guillona, , Yi-Hua Janb, Diane E
    Bioorganic Chemistry 89 (2019) 103014 Contents lists available at ScienceDirect Bioorganic Chemistry journal homepage: www.elsevier.com/locate/bioorg Phototoxicity of 7-oxycoumarins with keratinocytes in culture T ⁎ Christophe Guillona, , Yi-Hua Janb, Diane E. Heckc, Thomas M. Marianob, Robert D. Rappa, Michele Jettera, Keith Kardosa, Marilyn Whittemored, Eric Akyeaa, Ivan Jabine, Jeffrey D. Laskinb, Ned D. Heindela a Department of Chemistry, Lehigh University, Bethlehem, PA 18015, USA b Department of Environmental and Occupational Health, Rutgers University School of Public Health, Piscataway, NJ 08854, USA c Department of Environmental Science, New York Medical College, Valhalla, NY 10595, USA d Buckman Laboratories, 1256 N. McLean Blvd, Memphis, TN 38108, USA e Laboratoire de Chimie Organique, Université Libre de Bruxelles, B-1050 Brussels, Belgium ARTICLE INFO ABSTRACT Keywords: Seventy-one 7-oxycoumarins, 66 synthesized and 5 commercially sourced, were tested for their ability to inhibit 7-hydroxycoumarins growth in murine PAM212 keratinocytes. Forty-nine compounds from the library demonstrated light-induced 7-oxycoumarins lethality. None was toxic in the absence of UVA light. Structure-activity correlations indicate that the ability of Furocoumarins the compounds to inhibit cell growth was dependent not only on their physiochemical characteristics, but also Psoralens on their ability to absorb UVA light. Relative lipophilicity was an important factor as was electron density in the Methoxsalen pyrone ring. Coumarins with electron withdrawing moieties – cyano and fluoro at C – were considerably less 8-MOP 3 Phototoxicity active while those with bromines or iodine at that location displayed enhanced activity. Coumarins that were PAM212 keratinocytes found to inhibit keratinocyte growth were also tested for photo-induced DNA plasmid nicking.
    [Show full text]
  • Part IV: Basic Considerations of the Psoralens
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector THE CHEMISTRY OF THE PSORALENS* W. L. FOWLKS, Ph.D. The psoralens belong to a group of compoundsfled since biological activity of the psoralens and which have been considered as derivatives ofangelicins has been demonstrated. They appear coumarin, the furocoumarins. There are twelveto have specific biochemical properties which different ways a furan ring can be condensed withmay contribute to the survival of certain plant the coumarin molecule and each of the resultingspecies. Specifically these compounds belong to compounds could be the parent for a family ofthat group of substances which can inhibit certain derivatives. Examples of most of these possibleplant growth without otherwise harming the furocoumarins have been synthesized; but natureplant (2, 3, 5). is more conservative so that all of the naturally It is interesting that it was this property which occurring furocoumarins so far described turnled to the isolation of the only new naturally out to be derivativesof psoralen I or angelicinoccuring furocoumarin discovered in the United II (1). States. Bennett and Bonner (2) isolated tharn- nosmin from leaves of the Desert Rue (Tham- n.osma montana) because a crude extract of this 0 0 plant was the best growth inhibitor found among /O\/8/O\/ the extracts of a number of desert plants sur- i' Ii veyed for this property, although all the extracts showed seedling growth inhibition. One could I II speculate as to the role such growth inhibition plays in the economy of those desert plants These natural derivatives of psoralen and angeli-when survival may depend upon a successful cm have one or more of the following substituentsfight for the little available water.
    [Show full text]
  • Appendix Human and Rat Liver Cytochromes P450: Functional
    Appendix Human and Rat Liver Cytochromes P450: Functional Markers, Diagnostic Inhibitor Probes, and Parameters Frequently Used in P450 Studies Maria Almira Correia The tables in this appendix summarize the rel­ different P450 isoforms included in its evaluation ative functional selectivities of substrates and as well as the range of substrate/inhibitor concen­ inhibitors for the major human and rat liver trations tested. Second, substrates and inhibitors C3^ochrome P450 isoforms (P450s). These hepatic determined to be "relatively selective" for a human isoforms are well recognized to catalytically par­ liver isoform, may not necessarily be so for its rat ticipate in the metabolism of chemically diverse liver ortholog, and vice versa. Third, the relative endo- and xenobiotics including drugs, and in the metabolic contribution of a P450 isoform to the case of human liver P450s to thus contribute to in vivo hepatic metabolism of a given drug is directly clinically adverse drug-drug interactions. Conse­ proportional to the relative hepatic microsomal quently, these P450s are the targets of intense abundance of that isoform and its affinity for that scrutiny in the pharmaceutical screening of exist­ compound, irrespective of its in vitro high meta­ ing or novel chemical agents of potential clinical bolic profile assessed under "optimized" condi­ relevance for drug development. At a more basic tions. This issue arises because recent advances in level, these tables provide information on estab­ recombinant P450 technology have made unprece­ lished and/or potential diagnostic tools for the dented amounts of purified human liver enzymes identification and/or characterization of the meta­ readily available for comparative in vitro charac­ bolic role of each individual P450 in the disposition terization of drug metabolism, at relative P450 of an as yet uncharacterized xeno- or endobiotic.
    [Show full text]
  • Identification and Functional Characterization of the First Two
    Identification and functional characterization of the first two aromatic prenyltransferases implicated in the biosynthesis of furanocoumarins and prenylated coumarins in two plant families: Rutaceae and Apiaceae Fazeelat Karamat To cite this version: Fazeelat Karamat. Identification and functional characterization of the first two aromatic prenyl- transferases implicated in the biosynthesis of furanocoumarins and prenylated coumarins in two plant families: Rutaceae and Apiaceae. Agronomy. Université de Lorraine, 2013. English. NNT : 2013LORR0029. tel-01749560 HAL Id: tel-01749560 https://hal.univ-lorraine.fr/tel-01749560 Submitted on 29 Mar 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. AVERTISSEMENT Ce document est le fruit d'un long travail approuvé par le jury de soutenance et mis à disposition de l'ensemble de la communauté universitaire élargie. Il est soumis à la propriété intellectuelle de l'auteur. Ceci implique une obligation de citation et de référencement lors de l’utilisation de ce document. D'autre part, toute contrefaçon, plagiat,
    [Show full text]
  • Evaluation of Methoxsalen in the Treatment of Vitiligo Irving D
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector EVALUATION OF METHOXSALEN IN THE TREATMENT OF VITILIGO IRVING D. LONDON, M.D. Montgomery, Atabamo The value of the psoralen compounds in theviolet light from a General Electric R.S. Sunlamp treatment of vitiligo has been documented inbulb. The amount of exposure was gradually in- this country since 1952 (1—6). Vitiligo is a dis-creased, based on the patient's tolerance. Another ease of unknown etiology in which the pigmentgroup was treated by topical application of one rarely if ever has been known to return spon-per cent methoxsalen paint over small patches of vitiligo followed by exposure to sunlight or sun- taneously to the involved areas (see p. 281).lamp. At first, both 8-methoxypsoralen (methox- No statistical analysis will be attempted in this salen) and 8-isoamylenoxypsoralen were usedpaper for several reasons. First, several patients together in capsules for oral administration andwere lost from view after several months of treat- mixed in a cream for topical use. Since 1955,ment. Some were seen at distant clinics and these only methoxsalen has been used, after Kanofrecords were not available during the preparation (5) found that this compound was as effectiveof this paper. A few patients had to stop taking when used alone as when combined with 8-the drug because of toxic reactions. Lastly, the isoamylenoxypsoralen. When methoxsalen, eithertechnics of administration of the psoralens were not always comparable. I shall, therefore, discuss applied topically or taken orally, is followed bynot statistics but the results in general of the exposure to gradually increasing doses of sun-various technies especially as they pertain to light or artificial ultraviolet light, gradual re-individual patients.
    [Show full text]
  • Psoralen Photochemistry and Nucleic Acid Structure
    0022-202X/ 8 1/ 770 1-00J9$02.00/ 0 THE JOURNAL OF I NV r, STIGATIVE DEIlMATOLOGY, 77:39-44, IH8 1 Vol. 77, No. I Copy righ t © 198 1 by The Williams & Wilkins Co. Printed ill U.S.A. Psoralen Photochemistry and Nucleic Acid Structure JOHN E. H EARST, PH.D. Departm.ent of Chemistry, University of California, B erkeley, California, U.S.A . Many new psorale n derivatives have b een synthesized nated in the production of many new psoralens, several of which in an effort to enhance their water solubility and their have superior photoreactivity with both DNA and RNA as binding to nucleic acids. Availability of the very soluble compared to TMP and 8-MOP. The 5 new derivatives shown strongly binding compounds has improved our abilities here are 4' adducts of TMP and their structW"es ru-e shown (3 - to follow the optical changes associated with the photo­ 7). T he complete characterization of methoxymethyltrioxsalen chemistry of psoralens with DNA. Changes in both ab­ (MMT, 4) , hydroxymethyltrioxsalen (HMT, 5) and aminome­ sorbance and fluoresce nce are prese nted in this r eview. thyltrioxsalen (AMT, 7) wi th respect to their reactivity with A kinetic model for the photochemistry concludes that nucleic acids, including a theoretical treatment, is described in the detailed kinetics is dominated by the equilibrium a recent paper by Isaacs et al [6]. A related set of soluble 8- constant for intercalation of the psoralen in the DNA, methoxypsoralen derivatives have been synthesized by Isaacs, the quantum yield for photoaddition to DNA once inter­ Chun, a nd Hearst [7] a nd ru'e listed as compounds 8-11.
    [Show full text]
  • Bergapten Drives Autophagy Through the Up-Regulation of PTEN
    De Amicis et al. Molecular Cancer (2015) 14:130 DOI 10.1186/s12943-015-0403-4 RESEARCH Open Access Bergapten drives autophagy through the up-regulation of PTEN expression in breast cancer cells Francesca De Amicis1,2†, Saveria Aquila1,2*†, Catia Morelli1, Carmela Guido2, Marta Santoro2, Ida Perrotta3, Loredana Mauro1, Francesca Giordano1, Alessandra Nigro3, Sebastiano Andò1,2* and Maria L. Panno1* Abstract Background: Bergapten (5-methoxypsoralen), a natural psoralen derivative present in many fruits and vegetables, has shown antitumoral effects in a variety of cell types. In this study, it has been addressed how Bergapten in breast cancer cells induces autophagic process. Results: In MCF7 and ZR-75 breast cancer cells Bergapten exhibited anti-survival response by inducing the autophagic process increasing Beclin1, PI3KIII, UVRAG, AMBRA expression and conversion of LC3-I to LC3-II. LC3-GFP, Acridine orange assay and transmission electron microscopy even confirmed the increased autophagosome formations in treated cells. Bergapten-induced autophagy is dependent by PTEN up-regulation, since silencing this gene, the induction of Beclin1 and the p-AKT/p-mTOR signal down-regulation were reversed. PTEN is transcriptionally regulated by Bergapten through the involvement of p38MAPK/NF-Y, as evidenced by the use of p38MAPK inhibitor SB203580, site-direct mutagenesis of NF-Y element and NF-Y siRNA. Furthermore NF-Y knockdown prevented Bergapten-induced acid vesicular organelle accumulations (AVOs), strengthening the role of this element in mediating autophagy. Conclusions: Our data indicate PTEN as a key target of Bergapten action in breast cancer cells for the induction of autophagy. These findings add further details on the mechanism of action of Bergapten, therefore suggesting that phytochemical compounds may be implemented in the novel strategies for breast cancer treatment.
    [Show full text]
  • Dimethyl Fumarate for Plaque Psoriasis
    Horizon Scanning Centre November 2013 Dimethyl fumarate for plaque psoriasis SUMMARY NIHR HSC ID: 7758 Dimethyl fumarate is intended to be used for the treatment of moderate to severe plaque psoriasis. If licensed dimethyl fumarate may present an additional treatment option for this patient group, potentially delaying or avoiding the need for biological therapies. Dimethyl fumarate is one of three fumaric acid salts present in Fumaderm, a drug already licensed in Germany for plaque psoriasis. This briefing is Plaque psoriasis is the most common type of psoriasis, representing 90% of based on cases. The estimated UK prevalence of psoriasis is 1.5-1.63%, with 1.1% of information suffering with severe disease. It has a bimodal onset, with the first peak available at the time occurring in persons aged 16 to 22 years, and the second in persons aged of research and a 57 to 60 years. The prevalence of psoriasis in those younger than 10 years is limited literature estimated to be 0.55% and 1.4% in those aged between 10 and 19 years. search. It is not The estimated prevalence of people currently eligible for biological therapy in intended to be a England is 1.1% of those with psoriasis. Chronic plaque psoriasis is typified definitive statement by itchy, well demarcated circular-to-oval bright red/pink elevated lesions on the safety, (plaques) with overlying white or silvery scale, distributed symmetrically over efficacy or extensor body surfaces and the scalp. Current treatment options include effectiveness of the topical ointments and emollients, phototherapy, systemic therapies (e.g.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,563,754 B2 Orlow Et Al
    US008563754B2 (12) United States Patent (10) Patent No.: US 8,563,754 B2 Orlow et al. (45) Date of Patent: Oct. 22, 2013 (54) COMPOUNDS, COMPOSITIONS AND FOREIGN PATENT DOCUMENTS METHODS FOR PREVENTING SKIN JP 2004-352658 * 12/2004 DARKENING WO 99.09011 2, 1999 WO 9964O25 12/1999 (75) Inventors: Seth J. Orlow, New York, NY (US); Li WO OO62742 10, 2000 Ni Komatsu, Clarksville, MD (US) WO 01.01131 1, 2001 WO O2098347 12/2002 WO 2007110415 10/2007 (73) Assignee: New York University, New York, NY WO WO2O11,068595 * 6, 2011 (US) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Silverman et al., “The Organic Chemistry of Drug Design and Drug patent is extended or adjusted under 35 Action” Published 1992 by Academic Press, pp. 352-397.* U.S.C. 154(b) by 320 days. Vippagunta et al., “Crystalline Solids' Advanved Drug Delivery Reviews (2001) vol. 48 pp. 3-26.* Jain et al., “Polymorphism in Pharmacy” Indian Drugs (1986) vol. 23 (21) Appl. No.: 13/015,882 No. 6 pp. 315-329.* Braga et al., “Making Crystals from Crystals: a green route to crystal (22) Filed: Jan. 28, 2011 engineering and polymorphism” Chemcomm (2005) pp. 3635 3645.* (65) Prior Publication Data Lieberman et al., “Pharmaceutical Dosage Forms: Tablets' published 1990 by Marcel Dekker, Inc., pp. 462-472.* US 2011 FO190229 A1 Aug. 4, 2011 English machine translation of JP2004-352658, published Dec. 6. 2004. Suzuki et al., “Cancer Preventive Agents. Part5. Anti-tumor-Promot ing Effects of Coumarins and Related Compounds on Epstein-Barr Related U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano Et Al
    US 20090269772A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano et al. (43) Pub. Date: Oct. 29, 2009 (54) SYSTEMS AND METHODS FOR Publication Classification IDENTIFYING COMBINATIONS OF (51) Int. Cl. COMPOUNDS OF THERAPEUTIC INTEREST CI2O I/68 (2006.01) CI2O 1/02 (2006.01) (76) Inventors: Andrea Califano, New York, NY G06N 5/02 (2006.01) (US); Riccardo Dalla-Favera, New (52) U.S. Cl. ........... 435/6: 435/29: 706/54; 707/E17.014 York, NY (US); Owen A. (57) ABSTRACT O'Connor, New York, NY (US) Systems, methods, and apparatus for searching for a combi nation of compounds of therapeutic interest are provided. Correspondence Address: Cell-based assays are performed, each cell-based assay JONES DAY exposing a different sample of cells to a different compound 222 EAST 41ST ST in a plurality of compounds. From the cell-based assays, a NEW YORK, NY 10017 (US) Subset of the tested compounds is selected. For each respec tive compound in the Subset, a molecular abundance profile from cells exposed to the respective compound is measured. (21) Appl. No.: 12/432,579 Targets of transcription factors and post-translational modu lators of transcription factor activity are inferred from the (22) Filed: Apr. 29, 2009 molecular abundance profile data using information theoretic measures. This data is used to construct an interaction net Related U.S. Application Data work. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the (60) Provisional application No. 61/048.875, filed on Apr.
    [Show full text]
  • WO 2012/074588 A2 7 June 2012 (07.06.2012) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/074588 A2 7 June 2012 (07.06.2012) W P O P C T (51) International Patent Classification: Not classified (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, PCT/US201 1/049691 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 30 August 201 1 (30.08.201 1) HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (25) Filing Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, (30) Priority Data: TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 61/378,057 30 August 2010 (30.08.2010) US 61/478,700 25 April 201 1 (25.04.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US) : PRESID¬ GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ENT AND FELLOWS OF HARVARD COLLEGE ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
    [Show full text]